WENTWORTH TIMOTHY C 4

What Happened
Timothy C. Wentworth, a director of Quest Diagnostics (DGX), was granted 144 phantom stock units on 2026-07-01. The units show an acquisition price of $0.00 (derivative award) — this is a grant/deferral of compensation, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-01; filing date (Form 4): 2026-07-02. Filing appears timely.
• Reported transaction: Grant/Award (code A) of 144 phantom stock units @ $0.00.
• Shares/units owned after transaction: not specified in the filing.
• Footnote: These are phantom stock units from elective deferrals under the Quest Diagnostics Amended and Restated Deferred Compensation Plan for Directors and become payable in cash when the director’s service ends (see F1).
• No 10b5-1, tax-withholding, or immediate sale noted.

Context
Phantom stock units are a form of deferred cash compensation that track stock value but are settled in cash upon termination or as specified by the plan; they do not represent immediate ownership of common shares or voting rights. This transaction is a routine director compensation deferral rather than a market signal of buying or selling.